Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Andamios únicos para terapia celular in vitro e investigación y desarrollo farmacológico

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOEE20160629001
Publicado:
16/09/2016
Caducidad:
16/09/2017
Resumen:
Un equipo de investigación de una universidad estonia, con potencial para crear una spin-off, ofrece una tecnología de andamios personalizados para modelos de tumor en investigación con células madre, farmacología y otras aplicaciones. La anisotropía ultra alta combinada con otras características ofrece una nueva aplicación de transducción de señales, mejorando la terapia celular e investigación de medicamentos (probados en un entorno de producción piloto y validados en un laboratorio independiente). El equipo de investigación busca socios industriales e inversores.

Details

Tittle:
An Estonian research group offers unique scaffolds for in vitro cell therapy, pharmacology research and development looking for industrial- and investor partners worldwide.
Summary:
Estonian research group from university (with potential spin-off options) offers a customized scaffolds technology for stem cell research tumour models, pharmacology and other applications. The ultra-high anisotropy combined with other features enables new application of signals transduction, enhancing cell therapy and drug research (tested in pilot production and validated in independent laboratory). The group is looking for industrial and investor partners worldwide.
Description:
The Estonian university team has developed new technology and the material solution for the cell research, tissue engineering, pharmaceutical and other similar medical applications.
The development of solutions for both improved longevity of medical devices and the biospecificity of drug carriers and contrast agents is critical in modern medicine. The hostile environment can be simulated by use of specific synthetic materials to support cell-specific recognition and therapy process. Currently, there is no yet proven substrate biomaterial able for anisotropic control of cells phenotype, especially if the cells to be cultured are adult mesenchymal stem cells (MSC) or cancer cells.
The rational design of drug or cell-based therapy cannot be done unless a better understanding of effect of biological environment, drug delivery, mechanism of degradation, cells fate, and control of tissue-biomaterial interaction. Control of any inflammation process in a tissue regeneration context is also of paramount importance. This approach is becoming crucial for the research, diagnosis, management and treatment of critical pathology such as: neurodegenerative disorders (e.g. Alzheimer´s and Parkinson´s disease, multiple sclerosis), cardiovascular disorders, cancer, diabetes mellitus, etc.
The Estonian research group offers customized scaffolds, filling the gap between flat and volume options, providing a very high spatial and physical anisotropy capable to direct, divert and guide cell developments in non-conventional way essentially by bioinstructive surface design. These scaffolds could be considered as "2.5D culture", as they could be exploited in nearly flat and almost fully permeable setups.
New scaffolds are possible to apply in co-cultures, ALICE and bipolar assays with selective media separation, providing stable, self-aligned, cross-locked 15 to 550 billions of nanofibers per square centimeter area. New types of scaffolds have demonstrated clear influence of these substrates on cells (human mesenchymal stem cells and peripheral blood mononuclear cells) behaviour without use of extra factors and chemical compounds ("clean cultures"), suppressing or downregulating specific inflammation markers. In addition, new scaffolds were able to differentiate various tumour cell phenotypes into more or less directional proliferation, also capable of orthogonal cytoplasm capture (immobilization of cancer cells).
We are interested in the following principal cooperation types: financial, licensing and/or research cooperation. Under the first it means a potential investment in the spin-off company, making this new product. The second means licensing of the technology for the product manufacturing and application, supplying the users globally. The third means joint R-Y-D cooperation where this new product can be developed and further integrated in e.g. diagnostic or medical product systems. In all cases commercialization of the technology and the product is the main outcome.
We are looking for the international cooperation for the global market in these types. Financial cooperation offers the investor opportunity to gain a fast growth and profitability in this high-tech medical market. Licensing enables the partner to utilise this cutting-edge product, giving an added value and advantage to the customers. R-Y-D cooperation is envisaged with the medical product developers to produce new generation cell therapy and medical products.
Advantages and Innovations:
There are three main advantages to be explained in the following.
First, the scaffolds have very high anisotropy (~1000000:1) in substrate nanofiber size, stiffness, hydrophilicity and orientation. They are made of self-aligned, self-oriented and functionalized ceramic nanofibers (~40 nm) with high porosity (90-95%), withstanding extreme dry heat sterilization (over 1100°C). They also can be made electrically conductive or insulating.
Second, new features observed for human mesenchymal stem cells culturing were progressive orientation (towards neural line), downregulation of inflammatory cytokines, reduction of chemokines and suppression of IL1ß, TNFa, IFNg, IL2, IL4, IL12, complemented with confirmed absence Th1, autoimmune Th17 responses and reactive oxygen species scavenging.
And third, in tumour cells lines (tested with MDA-MB231, WM239A, Kelly, Caco2) unusual immobilization of cancer cells and reduction of cancer cells proliferation were recorded. Furthermore, anisotropic development of some phenotypes was possible to trigger and progress, not available with any other known scaffold or culture types.
Stage of Development:
Field tested/evaluated
IPs:
Secret Know-how,Patent(s) applied for but not yet granted,Copyright,Other
CommeR Statunts Regarding IPR Status:
US and PCT patent applications filed.

Partner sought

Type and Role of Partner Sought:
Financial cooperation partner: investment from a fund or company(ies); potential role: ownership/partnership or other forms.

Licensing partner: a company active in the field who likes to exploit or resell this new product but without forming a joint venture of similar. Potential role: licensing agreement for global marketing.

Research cooperation partner: company or CRO willing to make further joint R-Y-D cooperation for applications of this new product. Potential role: joint research funding; product development.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
Estonian
Finnish

Keywords

Technology Keywords:
06001024 Biomateriales médicos
06001003 Citología, cancerología, oncología
06004 Micro y nanotecnología relacionada con las ciencias biológicas
02007024 Nanomaterials
06001019 Tecnologías de células madre